



Prospective Analysis of Presenting Features of Neonatal Cholestasis – Limitations in Predictive Models of Biliary Atresia

Atlanta • Baltimore • Chicago • Cincinnati • Denver • Houston • Indianapolis • Los Angeles • New York • Philadelphia • Pittsburgh • St. Louis • San Francisco • Seattle • Toronto


B Shneider, J Magee, N Kerkar, J Moore, W Ye, S Karpen, P Whittington, J Bezerra, P Hertel, J Molleston, K Wang, H Lin, R Squires, P Rosenthal, V Ng, Y Turmelle, K Schwarz, K Murray, A Sherker, R Sokol for the Childhood Liver Disease Research Network (ChILDReN)



Research Sites




★ Clinical Sites
● DCC
● NIH



Introduction

- ▣ Neonatal cholestasis is the presentation of a wide spectrum of serious disorders
- ▣ Timely and organized investigation is important
- ▣ In particular for biliary atresia





Can one differentiate biliary atresia (BA) from nonBA at presentation?
Informing clinical decision-making vis a vis further invasive testing



Hypothesis – Clinical parameters at presentation can be used to develop a model that precisely distinguishes BA from nonBA



Methods – Prospective Database of Infants with Cholestasis (PROBE)

- ▣ PROBE – April 2004 to February 2014
- ▣ Inclusion
 - ▣ Age < 180 days
 - ▣ DB or CB \geq 2 mg/dL
- ▣ Exclusion
 - ▣ Acute liver failure, previous hepatobiliary surgery, sepsis, hypoxia, shock, malignancy, primary hemolytic disease, TPN-associated cholestasis, ECMO-associated cholestasis, BW < 1500g

NCT 00061828



Methods – Definitions

- ▣ BA
 - ▣ Hepatopertoenterostomy for BA, or
 - ▣ Exploration consistent with BA
- ▣ nonBA
 - ▣ Specific diagnosis associated with cholestasis
 - ▣ Idiopathic Neonatal Hepatitis (INH) or Idiopathic Cholestasis (IC) required $TB \leq 1.0$ at ≥ 120 days of age



Methods – Parameters

- ▣ PROBE Enrollment = presentation
- ▣ Clinical features
 - ▣ **History**- age at disease onset and at first evaluation, acholic stools, gender, race, ethnicity
 - ▣ **Physical examination** – weight, length, head circumference, MAC, facial features, liver BCM, spleen
 - ▣ **Laboratory results** – Total Bilirubin, Direct/Conjugated Bilirubin, ALT, AST, γ GTP, Alk phos, alb, platelet count, cholesterol
 - ▣ **Gallbladder sonography** – present or absent (present includes "small")




Methods - Analysis

- ▣ Primary analysis – BA vs nonBA
- ▣ Univariate
- ▣ Prediction Model Development
 - ▣ Logistic multivariate regression analysis (backward stepwise selection using $\alpha=0.10$ as the selection criteria)
 - ▣ Hierarchical classification and regression tree (CART)
 - ▣ AUC ROC
 - ▣ Classification



Results - Diagnoses





Results – Significant differences between BA and nonBA


	BA	nonBA
Female gender	52.4%	36.7%
Disease onset (days)	12.8 ± 18.5	18.7 ± 22.1
Wt z-score	-1.0 ± 1.0	-1.5 ± 1.2
Length z-score	-0.8 ± 1.5	-1.4 ± 1.5
Head circumference z-score	-1.1 ± 1.6	-1.4 ± 1.2
Acholic stools	82.4%	34.0%
Abnormal facial features	4.8%	18.8%



Results – Significant differences between BA and nonBA


	BA	nonBA
Liver below costal margin (cm)	3.3 ± 1.6	2.5 ± 1.4
Palpable spleen	50.0%	40.4%
Albumin (g/dL)	3.6 ± 0.5	3.5 ± 0.6
γGTP (IU/L)	712 ± 538	299 ± 380
Platelet count (x10 ⁹ /L)	445 ± 180	420 ± 197
Absent gallbladder	39.9%	6.5%

Results – Logistic Regression ROC




- Step 1 – acholic stools
- Step 2 – γ GTP
- Step 3 – GB absent
- Step 4 – Facial features
- Step 5 – Liver BCM
- Step 6 – Weight z-score
- Step 7 – Gender
- Step 8 – ALT
- Step 9 – disease onset

Results – Logistic Regression ROC



- Step 1 – acholic stools
- Step 2 – γ GTP
- Step 3 – GB absent
- Step 4 – Facial features
- Step 5 – Liver BCM
- Step 6 – Weight z-score
- Step 7 – Gender
- Step 8 – ALT
- Step 9 – disease onset


Results – Predicted Probability



* 224 infants predicted probability between 0.2 and 0.8




Results – Predicted Probability



* 224 infants predicted probability between 0.2 and 0.8




Results – Predicted Probability





* 224 infants predicted probability between 0.2 and 0.8





Results - CART Analysis











Results -

<p><u>Missed BA</u></p> <ul style="list-style-type: none"> ▣ Predicted probability < 0.2 predicted nonBA = 136 <ul style="list-style-type: none"> ▣ True nonBA = 120, ▣ Missed BA = 16 (11.7%) ▣ CART – 16.5% erroneously categorized as nonBA 	<p><u>Overcalled BA</u></p> <ul style="list-style-type: none"> ▣ Predicted probability > 0.8 predicted BA = 357 <ul style="list-style-type: none"> ▣ True BA = 290, ▣ "Extra" investigations in 67 (18.8%) ▣ CART – 20.8% erroneously categorized as BA
--	---

Conclusions

- ▣ Significant differences exist in clinical features at presentation in BA vs nonBA
- ▣ Modeling not sufficiently precise to permit "highly informed" decisions based upon presenting clinical features
 - ▣ 10 – 20% chance to miss BA without further investigation
 - ▣ ~20% of infants undergo further investigations without BA
- ▣ Caution against making definitive decisions based upon these presenting clinical features in neonatal cholestasis
